Opus Genetics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on April 20, 2026. Opus Genetics, Inc. (Nasdaq: IRD) is a Delaware corporation focused on genetic medicine. The filing details the outcomes of four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders approved all four proposals presented at the Annual Meeting:
- Board Election: Nine directors were elected to one-year terms. All nominees received majority support, though Dr. James S. Manuso received a higher number of withheld votes (1,348,112) compared to other nominees.
- Auditor Ratification: Ernst & Young, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Say-On-Pay: The compensation of named executive officers was approved on an advisory basis.
- Stock Increase: An amendment to the Restated Certificate of Incorporation was approved to increase authorized common stock from 125 million to 250 million shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the impact of the authorized share increase (doubling from 125 million to 250 million) on potential future dilution.
- Review the specific reasons for the higher number of votes withheld for director nominee Dr. James S. Manuso compared to other board members.
- Confirm the effective date of the charter amendment regarding the increased share authorization.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.